Estrogen is known to enhance the growth and migration of breast cancer cells. Now researchers at the University of Illinois at Urbana-Champaign have found that estrogen also can shield breast cancer cells from immune cells.
Radiotherapy after breast conserving surgery for breast cancer reduces recurrence and prevents development of additional breast tumors in older women with early stage breast disease, according to a new study.
A new study says early termination of the highly effective breast cancer drug tamoxifen may negatively affect treatment efficacy.
Radiation therapy after lumpectomy and five years of treatment with the drug tamoxifen can dramatically reduce the risk of both cancer recurrence and new tumors in older women with early breast cancer.
Women who took more control over choosing their breast cancer surgeon were more likely to be treated by more experienced breast surgeons and at a hospital affiliated with an accredited cancer program, compared to women who were referred by another doctor or their health plan, according to a study led by researchers at the University of Michigan Comprehensive Cancer Center.
A surprising discovery by Queen’s University researchers that happened when their work took an unexpected turn may help women with advanced breast cancer respond better to conventional drug treatments.
Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.
The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Berkeley Lab researchers have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.
A new study using mastectomy tissue shows that precancerous changes can occur in normal-appearing areas of the breast as distant as two inches from a tumor’s edge. The findings, while preliminary, might have important implications for identifying breast-cancer patients at high risk of a second tumor in the same breast.
Herceptin improves early survival for women with breast cancer, revealed in the Lancet report. Giving Herceptin to women with a certain type of breast cancer for one year following standard chemotherapy may improve their survival.